Since all of the genetic experiments were performed in germline Il1a/b- or Il1b-deficient mice, we sought to determine whether locally neutralizing IL-1β or introducing an IL-1R1 antagonist (IL-1Ra) would impede tumor growth and prolong the survival of tumor-bearing mice without interfering with normal development and function of immune cells. This evidence concerns the gene IL1B and neoplasm.